ArticleBreast cancer research : BCR2017

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.

Natalia Paez Arango et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.